These findings suggest that T2 and PDE4 overexpression in COPD patients with higher sputum eosinophil counts contributes to the differential clinical response to PDE4 inhibitors observed in previous clinical trials.4, 10. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.